Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Carbone

Showing results (581-590 of 651) with videos related to

Pageof 66
Sort By:
Journal of Geriatric Oncology|February 25, 2021
Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancerAndrew C Johns, Lai Wei, Madison Grogan, et al.
Science Translational Medicine|January 28, 2026
SREBP-1 increases glucose uptake to promote tumor resistance to lysosome inhibitionYaogang Zhong, Feng Geng, Huali Su, et al.
Molecular & Cellular Proteomics : MCP|July 5, 2012
In-depth proteomic analysis of nonsmall cell lung cancer to discover molecular targets and candidate biomarkersTakefumi Kikuchi, Mohamed Hassanein, Joseph M Amann, et al.
Lung Cancer (Amsterdam, Netherlands)|November 15, 2025
Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapyAdam Khorasanchi, Mingjia Li, Songzhu Zhao, et al.
Cancer Investigation|October 10, 2025
Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint InhibitorsSandip H Patel, Songzhu Zhao, Mingjia Li, et al.
Journal of the National Cancer Institute|June 7, 2007
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional studyFumiko Taguchi, Benjamin Solomon, Vanesa Gregorc, et al.
BMC Cancer|May 8, 2020
Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medicationsDaniel Spakowicz, Rebecca Hoyd, Mitchell Muniak, et al.
Cancer|January 29, 2025
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancerJacob M Sands, Stéphane Champiat, Horst-Dieter Hummel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2005
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancerRoy S Herbst, David H Johnson, Eric Mininberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2005
Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcomeDavid P Carbone, I Frank Ciernik, Michael J Kelley, et al.
Pageof 66

Showing results (581-590 of 651) with videos related to

Sort By:
Pageof 66
Journal of Geriatric Oncology|February 25, 2021
Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancerAndrew C Johns, Lai Wei, Madison Grogan, et al.
Science Translational Medicine|January 28, 2026
SREBP-1 increases glucose uptake to promote tumor resistance to lysosome inhibitionYaogang Zhong, Feng Geng, Huali Su, et al.
Molecular & Cellular Proteomics : MCP|July 5, 2012
In-depth proteomic analysis of nonsmall cell lung cancer to discover molecular targets and candidate biomarkersTakefumi Kikuchi, Mohamed Hassanein, Joseph M Amann, et al.
Lung Cancer (Amsterdam, Netherlands)|November 15, 2025
Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapyAdam Khorasanchi, Mingjia Li, Songzhu Zhao, et al.
Cancer Investigation|October 10, 2025
Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint InhibitorsSandip H Patel, Songzhu Zhao, Mingjia Li, et al.
Journal of the National Cancer Institute|June 7, 2007
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional studyFumiko Taguchi, Benjamin Solomon, Vanesa Gregorc, et al.
BMC Cancer|May 8, 2020
Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medicationsDaniel Spakowicz, Rebecca Hoyd, Mitchell Muniak, et al.
Cancer|January 29, 2025
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancerJacob M Sands, Stéphane Champiat, Horst-Dieter Hummel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2005
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancerRoy S Herbst, David H Johnson, Eric Mininberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2005
Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcomeDavid P Carbone, I Frank Ciernik, Michael J Kelley, et al.
Pageof 66